Market revenue in 2023 | USD 329.1 million |
Market revenue in 2030 | USD 1,097.0 million |
Growth rate | 18.8% (CAGR from 2023 to 2030) |
Largest segment | Adeno-associated virus (aav) |
Fastest growing segment | Adeno-associated virus (AAV) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Adeno-associated virus (AAV), Lentivirus, Adenovirus, Retrovirus, Plasmids |
Key market players worldwide | Merck KGaA, Lonza Group Ltd, FUJIFILM Holdings Corp, Thermo Fisher Scientific Inc, Catalent Inc, WuXi Biologics (Cayman) Inc, Takara Bio Inc, Batavia Biosciences, Miltenyi Biotec, Revvity Inc, BioNTech SE ADR, Astellas Pharma Inc, Biomarin Pharmaceutical Inc, Regenxbio Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to viral vector and plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Adeno-associated virus (aav) was the largest segment with a revenue share of 19.9% in 2023. Horizon Databook has segmented the Germany viral vector and plasmid dna manufacturing market based on adeno-associated virus (aav), lentivirus, adenovirus, retrovirus, plasmids covering the revenue growth of each sub-segment from 2018 to 2030.
Germany is one of the leading gene therapy clinical trials country in Europe. A substantial number of companies have their facilities set up here, which is anticipated to support the rapid commercialization of drugs. Germany is the first country where the recently approved gene therapy treatment has been utilized.
It is expected to witness significant growth in the number of trials and approval of drugs in the coming years, owing to an increase in the number of companies being set up and the support provided by governments in finding feasible treatment options for genetic disorders & various cancers.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany viral vector and plasmid dna manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Germany viral vector and plasmid dna manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account